0 CHECKOUT

Autism - Pipeline Review, H2 2015

  • ID: 3404575
  • August 2015
  • 131 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • BioCrea GmbH
  • Cellceutix Corporation
  • Curemark, LLC
  • Egenix, Inc.
  • F. Hoffmann-La Roche Ltd.
  • MORE

Autism - Pipeline Review, H2 2015

Summary

The report ‘Autism - Pipeline Review, H2 2015’, provides an overview of the Autism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • BioCrea GmbH
  • Cellceutix Corporation
  • Curemark, LLC
  • Egenix, Inc.
  • F. Hoffmann-La Roche Ltd.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Autism Overview

Therapeutics Development

Pipeline Products for Autism - Overview

Pipeline Products for Autism - Comparative Analysis

Autism - Therapeutics under Development by Companies

Autism - Therapeutics under Investigation by Universities/Institutes

Autism - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Autism - Products under Development by Companies

Autism - Products under Investigation by Universities/Institutes

Autism - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

BioCrea GmbH

BrainStorm Cell Therapeutics Inc.

Cellceutix Corporation

Confluence Pharmaceuticals LLC

Curemark, LLC

Egenix, Inc.

F. Hoffmann-La Roche Ltd.

Heptares Therapeutics Limited

Intra-Cellular Therapies, Inc.

MedDay

Merz Pharma GmbH & Co. KgaA

Mnemosyne Pharmaceuticals, Inc.

Omeros Corporation

Otsuka Holdings Co., Ltd.

Retrophin Inc.

Reviva Pharmaceuticals Inc.

Saniona AB

Sumitomo Dainippon Pharma Co., Ltd.

Autism - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

acamprosate calcium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ADX-71441 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ADX-88178 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

aripiprazole - Drug Profile

Product Description

Mechanism of Action

R&D Progress

aripiprazole - Drug Profile

Product Description

Mechanism of Action

R&D Progress

carbetocin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CM-AT - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CN-2097 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug for Autism - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HTL-14242 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ITI-007 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KM-391 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lurasidone hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MD-1103 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

memantine hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

oxytocin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RG-7314 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RO-5285119 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RP-5063 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Modulate GABRA5 Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Target GPR63 for Autism - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

suramin hexasodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VU-0410120 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Autism - Recent Pipeline Updates

Autism - Dormant Projects

Autism - Discontinued Products

Autism - Product Development Milestones

Featured News & Press Releases

Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole

Jun 10, 2015: Clinical trial launched to assess safety and efficacy of autism drug treatment

May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism

Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment

Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism

Mar 13, 2013: Researchers Use Old Drug Treatment To Correct Autism Symptoms In Mouse Model

Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Autism, H2 2015

Number of Products under Development for Autism - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Autism - Pipeline by Addex Therapeutics Ltd, H2 2015

Autism - Pipeline by BioCrea GmbH, H2 2015

Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2015

Autism - Pipeline by Cellceutix Corporation, H2 2015

Autism - Pipeline by Confluence Pharmaceuticals LLC, H2 2015

Autism - Pipeline by Curemark, LLC, H2 2015

Autism - Pipeline by Egenix, Inc., H2 2015

Autism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015

Autism - Pipeline by Heptares Therapeutics Limited, H2 2015

Autism - Pipeline by Intra-Cellular Therapies, Inc., H2 2015

Autism - Pipeline by MedDay, H2 2015

Autism - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2015

Autism - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2015

Autism - Pipeline by Omeros Corporation, H2 2015

Autism - Pipeline by Otsuka Holdings Co., Ltd., H2 2015

Autism - Pipeline by Retrophin Inc., H2 2015

Autism - Pipeline by Reviva Pharmaceuticals Inc., H2 2015

Autism - Pipeline by Saniona AB, H2 2015

Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Autism Therapeutics - Recent Pipeline Updates, H2 2015

Autism - Dormant Projects, H2 2015

Autism - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Autism, H2 2015

Number of Products under Development for Autism - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Routes of Administration, H2 2015

Number of Products by Stage and Routes of Administration, H2 2015

Number of Products by Molecule Types, H2 2015

Number of Products by Stage and Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Addex Therapeutics Ltd
BioCrea GmbH
BrainStorm Cell Therapeutics Inc.
Cellceutix Corporation
Confluence Pharmaceuticals LLC
Curemark, LLC
Egenix, Inc.
F. Hoffmann-La Roche Ltd.
Heptares Therapeutics Limited
Intra-Cellular Therapies, Inc.
MedDay
Merz Pharma GmbH & Co. KgaA
Mnemosyne Pharmaceuticals, Inc.
Omeros Corporation
Otsuka Holdings Co., Ltd.
Retrophin Inc.
Reviva Pharmaceuticals Inc.
Saniona AB
Sumitomo Dainippon Pharma Co., Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.